Device Trial Radar · NCT03556696
Automatic Remifentanil Administration Guided by ANI During Propofol Anesthesia
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jun 27, 2018
Primary completion
Jun 14, 2022
Study completion Nov 22, 2022
Sponsor
- Lead sponsor
- University Hospital, LilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 14, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective Randomized Monocentric Clinical Trial during propofol anesthesia. The aim of the study is to test whether the use of a medical device designed to automatically administer remifentanil during surgery based on expert rules and continuous reading of heart rate, blood pressure and the Analgesia Nociception Index results in lower overall remifentanil administration versus standard practice.
Conditions
- Nociceptive Pain
- Surgical Procedure, Unspecified
Interventions
ANI-REMI-loopDevice
experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
remifentanil pK/pD target administration deviceDevice
standard practice, remifentanil administration using Minto's pK/pD model
RemifentanilDrug
Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
PropofolDrug
propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
ANI monitorDevice
ANI (Analgesia Nociception Index) value is used in the "std\_practice" arm for guidance of the remifentanil Ce target
Primary outcomes
What the sponsor says the trial is designed to measure.
- normalized remifentanil administrationTime frame: During the surgery, an average Three hours and a half
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Roger Salengro, CHU
Lille, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.